EP
TRDA icon

Essential Partners’s Entrada Therapeutics TRDA Stock Holding History

Essential Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39K Buy
597
+443
+288% +$4.25K ﹤0.01% 1605
2026
Q1 		$1.94K Buy
154
+103
+202% +$1.18K ﹤0.01% 2017
2025
Q4 		$524 Buy
51
+40
+364% +$337 ﹤0.01% 2221
2025
Q3 		$64 Buy
11
+6
+120% +$35 ﹤0.01% 2542
2025
Q2 		$34 Buy
+5
New +$40 ﹤0.01% 2184

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Essential Partners's TRDA Position: Q2 2026 in Review

Essential Partners increased its Entrada Therapeutics (TRDA) stake by 288% in Q2 2026, buying an estimated $4.25K and bringing the position to 597 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

Essential Partners first reported a position in TRDA in Q2 2025 and has held it in 5 quarters since. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Essential Partners held 597 shares of Entrada Therapeutics worth $4.39K as of Q2 2026.
  • Essential Partners bought 443 Entrada Therapeutics shares in Q2 2026, an estimated $4.25K.
  • Entrada Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1605 holding.
  • Essential Partners first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.